Compared to LUAD from patients with smoking history, NS-LUAD are thought to be less sensitive to immune checkpoint blockade (ICB) due to differences in tumor mutational burden and immune microenvironment, including PD-L1 expression(50) – two established markers predictive of ICB responses(51–56). The gene discussed is CD274; the disease is neoplasm.